Trials / Terminated
TerminatedNCT04614467
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Lisata Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Conditions
- Coronary Microvascular Dysfunction
- Coronary Microvascular Disease
- Microvascular Coronary Artery Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CLBS16 | GCSF-mobilized autologous CD34+ cells |
| BIOLOGICAL | Placebo | isotonic solution (no CD34+ cells) |
Timeline
- Start date
- 2020-10-29
- Primary completion
- 2022-09-28
- Completion
- 2022-09-28
- First posted
- 2020-11-04
- Last updated
- 2023-10-17
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04614467. Inclusion in this directory is not an endorsement.